

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7641665

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MERCK KGAA	09/24/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MERCK HEALTHCARE KGAA
<b>Street Address:</b>	FRANKFURTER STRASSE 250
<b>City:</b>	DARMSTADT
<b>State/Country:</b>	GERMANY
<b>Postal Code:</b>	64293
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	11485786
<b>Application Number:</b>	18050817
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	571-458-7790
<b>Email:</b>	patent@gandmpatent.com
<b>Correspondent Name:</b>	GRUNEBERG AND MYERS PLLC
<b>Address Line 1:</b>	1775 TYSONS BLVD.
<b>Address Line 2:</b>	5TH FLOOR
<b>Address Line 4:</b>	TYSONS, VIRGINIA 22102
<b>ATTORNEY DOCKET NUMBER:</b>	000615USCONT01-CONT02
<b>NAME OF SUBMITTER:</b>	ANGELA HENZ
<b>SIGNATURE:</b>	/Angela Henz/
<b>DATE SIGNED:</b>	11/11/2022
<b>Total Attachments: 3</b>	
source=000615USCONT01-02_Assignment-Merck KGaA to Merck Healthcare KGaA#page1.tif	
source=000615USCONT01-02_Assignment-Merck KGaA to Merck Healthcare KGaA#page2.tif	
source=000615USCONT01-02_Assignment-Merck KGaA to Merck Healthcare KGaA#page3.tif	

## PATENT ASSIGNMENT

WHEREAS, **Merck KGaA**, a corporation with general partners of Germany, having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany, (hereinafter "ASSIGNOR"), is the owner by a lawfully executed Assignment of all rights, title and interest in an invention(s), which invention(s) is described in an application(s) for Letters Patent, which application(s) are listed in the attached Schedule as may be amended from time-to-time; and

**Merck Healthcare KGaA**, a corporation with general partners of Germany, having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany, (hereinafter "ASSIGNEE") have entered into an agreement ("Agreement") wherein all intellectual property developed under such Agreement shall be held in the name of ASSIGNEE.

NOW, THEREFORE, pursuant to the above Agreement, the undersigned on behalf of ASSIGNOR has sold, assigned and transferred, and do hereby sell, assign and transfer unto ASSIGNEE, its lawful successors and assigns, the full, exclusive and worldwide right to the invention, and the entire right, title and interest in, to and under the application(s) and any and all Letters Patent(s) that may be granted on the application(s), any and all priority applications and Letters Patent thereof, any and all applications and Letters Patent claiming priority to the application(s), including any and all divisions or continuations thereof, any and all renewals, substitutes, reissues, reexaminations and extensions thereof, in the United States of America, in the territorial possessions of the United States of America, and equivalents thereto in any country foreign to the United States of America, including full right to claim for any such applications all benefits and priority rights under any applicable convention, the same to be held and enjoyed by ASSIGNEE, its lawful successors and assigns as fully and entirely as the same would have been held by ASSIGNOR had this assignment not been made.

ASSIGNOR hereby authorizes and requests the Commissioner of Patent and Trademarks of the United States of America and respective Patent Office officials in any country foreign to the United States of America to issue said Letters Patent to ASSIGNEE, and ASSIGNOR hereby further authorizes ASSIGNEE to apply for Letters Patent in ASSIGNOR name or in ASSIGNEE own name, as ASSIGNEE sees fit in its sole discretion, utilizing any benefits which may exist under any International Agreement, in any country.

ASSIGNOR hereby agrees for itself, its lawful successors, assigns and legal representatives to execute any lawful document and to testify as to any material fact or thing which ASSIGNEE, its lawful successors, assigns and legal representatives may deem necessary in order to secure unto ASSIGNEE, its successors and assigns the full right, title and interest in and to, and the full enjoyment of, the invention or any part thereof, the applications and any and all Letters Patent, the same to be done without any further consideration.

IN TESTIMONY WHEREOF, I hereby set my hand on behalf of Merck KGaA, this 24 day of September, 2020.

Signature: ppa. [Signature] i. V. [Signature]  
Name and Title: Dr. Stefan Horstmann Dr. Christian Brazel  
Vice President Director

**Witnesses:** I attest that on this day, the above person on behalf of Merck KGaA did sign above in my presence of his/her own free will.

Witness Signature: [Signature]

Witness Name: Claudia Spengler

Date: September 24, 2020

Witness Signature: [Signature]

Witness Name: Martina Bopp

Date: 24 September 2020

IN TESTIMONY WHEREOF, I hereby set my hand on behalf of Merck Healthcare KGaA, this 28 day of September, 2020.

Signature: ppa. [Signature] ppa. [Signature]  
Name and Title: Dr. Arno Hartmann Dr. Wolfgang Losert

**Witnesses:** I attest that on this day, the above person on behalf of Merck Healthcare KGaA did sign above in my presence of his/her own free will.

Witness Signature: [Signature]

Witness Name: Pia Reinhart

Date: 28. September 2020

Witness Signature: [Signature]

Witness Name: Birgit Schaffnit

Date: 28 September 2020

SCHEDULE

Application No.:	Country	Title	Filing Date	Inventor(s)
16/541,650	US	ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS	August 15, 2019	Ilhan Celik Eike Staub Miriam Urban Sabine Raab-Westphal Eileen Samy Andrew Bender Georgianna Varrone Yin Wu Daigen Xu

Date: November 2, 2022